Biohaven Shares Jump After Market Open

Analysts remain bullish on the pharmaceutical company despite recent stock volatility.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Biohaven Ltd. (NYSE:BHVN) saw its share price gap up before the market opened on Monday, rising from a previous close of $9.92 to open at $11.89. The stock later settled at $9.59, with over 2.6 million shares traded. Wall Street analysts remain largely bullish on Biohaven, with a consensus 'Moderate Buy' rating and an average price target of $23.93.

Why it matters

Biohaven is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and neurovascular diseases. Its stock has seen significant volatility in recent months, but the company's pipeline of migraine treatments and other drug candidates continue to generate interest from analysts and investors.

The details

Biohaven's share price jump on Monday came despite the company's stock having declined from a 52-week high of $47 down to around $9-$12 in recent months. Analysts have cited the company's strong pipeline, including its CGRP receptor antagonists for acute and preventive migraine treatment, as reasons for their continued optimism. However, the stock has faced headwinds due to factors like clinical trial results and broader market conditions.

  • Biohaven's share price opened at $11.89 on Monday, March 9, 2026, up from a previous close of $9.92.
  • Over the past 52 weeks, Biohaven's stock has ranged from a high of $47 to a low around $9-$12.

The players

Biohaven Ltd.

A clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases.

JPMorgan Chase & Co.

A major investment bank that has cut its price target on Biohaven shares from $47 to $15, while maintaining an 'overweight' rating.

Royal Bank of Canada

An investment bank that has boosted its price target on Biohaven shares from $22 to $23, while giving the stock an 'outperform' rating.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.